You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

DOXYLAMINE SUCCINATE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Doxylamine Succinate, and when can generic versions of Doxylamine Succinate launch?

Doxylamine Succinate is a drug marketed by Copley Pharm, LNK, Perrigo, Quantum Pharmics, Actavis Labs Fl Inc, Bionpharma, Endo Operations, and Mylan Pharms Inc. and is included in nine NDAs.

The generic ingredient in DOXYLAMINE SUCCINATE is doxylamine succinate; pyridoxine hydrochloride. There are fourteen drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the doxylamine succinate; pyridoxine hydrochloride profile page.

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for DOXYLAMINE SUCCINATE?
  • What are the global sales for DOXYLAMINE SUCCINATE?
  • What is Average Wholesale Price for DOXYLAMINE SUCCINATE?
Drug patent expirations by year for DOXYLAMINE SUCCINATE
Recent Clinical Trials for DOXYLAMINE SUCCINATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Jiamusi Maternal and Child Health HospitalPhase 3
Xuzhou Central HospitalPhase 3
First Affiliated Hospital of Heilongjiang Chinese Medicine UniversityPhase 3

See all DOXYLAMINE SUCCINATE clinical trials

Pharmacology for DOXYLAMINE SUCCINATE
Drug ClassAntihistamine
Mechanism of ActionHistamine Receptor Antagonists
Medical Subject Heading (MeSH) Categories for DOXYLAMINE SUCCINATE
Anatomical Therapeutic Chemical (ATC) Classes for DOXYLAMINE SUCCINATE

US Patents and Regulatory Information for DOXYLAMINE SUCCINATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Copley Pharm DOXYLAMINE SUCCINATE doxylamine succinate TABLET;ORAL 088900-002 Feb 12, 1988 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Endo Operations DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE doxylamine succinate; pyridoxine hydrochloride TABLET, DELAYED RELEASE;ORAL 208518-001 Dec 6, 2017 AB RX No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Quantum Pharmics DOXYLAMINE SUCCINATE doxylamine succinate TABLET;ORAL 088603-001 Aug 7, 1984 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Mylan Pharms Inc DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE doxylamine succinate; pyridoxine hydrochloride TABLET, DELAYED RELEASE;ORAL 207825-001 Jul 6, 2020 AB RX No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Lnk DOXYLAMINE SUCCINATE doxylamine succinate TABLET;ORAL 040564-001 Aug 27, 2004 OTC No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

DOXYLAMINE SUCCINATE Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory of Doxylamine Succinate

Introduction

Doxylamine succinate, a widely used antihistamine and sedative, is a key component in various over-the-counter (OTC) medications, including Nyquil. The market for doxylamine succinate is experiencing significant growth, driven by several factors. Here, we delve into the market dynamics, financial trajectory, and key aspects influencing this market.

Market Size and Growth

The global doxylamine succinate market has witnessed substantial growth in recent years. As of 2023, the market size was valued at several billion USD and is projected to expand further by 2031, exhibiting a notable compound annual growth rate (CAGR)[1][3].

Segmentation

The market is segmented based on several criteria:

  • Type: Solid and liquor forms are the primary types of doxylamine succinate available in the market[1][3].
  • Application: The drug is used as an antihistamine, anticholinergic, sedative, and in other applications[1][3].
  • Geography: The market is analyzed across regions such as North America, Europe, Asia-Pacific, South America, and the Middle East & Africa[1][3].

Drivers

Several factors are driving the growth of the doxylamine succinate market:

  • Increasing Demand for OTC Medications: The rising demand for over-the-counter medications, particularly for cold and flu relief, is a significant driver. Nyquil, which contains doxylamine succinate, is a popular choice for such conditions[2].
  • Expanding Healthcare Needs: Growing healthcare needs, especially in emerging economies, are contributing to the increased demand for antihistamines and sedatives[3].
  • Advancements in Pharmaceutical Technology: Improvements in pharmaceutical manufacturing and formulation are enhancing the efficacy and safety of doxylamine succinate products[3].

Restraints

Despite the growth, there are several restraints affecting the market:

  • Regulatory Challenges: Strict regulatory frameworks and the need for compliance can slow down market growth. Manufacturers must adhere to stringent guidelines to ensure the safety and efficacy of their products[1][3].
  • Misuse and Addiction: The misuse of doxylamine succinate, particularly in Nyquil, leading to addiction and health complications, is a significant concern. This can impact market perception and regulatory scrutiny[2].

Opportunities

The market presents several opportunities for growth:

  • Emerging Markets: Expanding into emerging economies where healthcare infrastructure is developing offers significant growth potential[3].
  • Innovative Formulations: Developing new formulations and delivery methods can attract more consumers and expand market share[3].

Challenges

The market faces several challenges:

  • Competition: The presence of numerous competitors, including both established and emerging players, makes the market highly competitive[1][3].
  • Economic Factors: Economic fluctuations and changes in consumer spending patterns can impact market growth[3].

Competitive Landscape

The competitive landscape of the doxylamine succinate market is characterized by:

  • Key Players: Companies such as Teva, CHATTEM, DUCHESNAY, LNK INTERNATIONAL INC, PERRIGO, Viatris (MYLAN), and others are prominent players in the market. These companies are focusing on expanding their product portfolios and geographical presence[1][3].
  • Market Positioning: The market positioning of these companies is influenced by their product/service portfolios, financial performance, strategic initiatives, and regional presence[1].

Financial Trajectory

The financial trajectory of the doxylamine succinate market is positive, with projected significant revenue growth from 2023 to 2031. Here are some key financial insights:

  • Revenue Growth: The market is expected to grow at a notable CAGR, driven by increasing demand and expanding applications[1][3].
  • Regional Performance: North America and Europe are currently leading the market, but Asia-Pacific is expected to show significant growth due to increasing healthcare needs and economic development[1][3].

Regional Analysis

The market performance varies across different regions:

  • North America: This region is a major market for doxylamine succinate, driven by high demand for OTC medications and a well-established healthcare system[1][3].
  • Europe: Europe also represents a significant market, with a strong focus on pharmaceutical innovation and regulatory compliance[1][3].
  • Asia-Pacific: This region is expected to experience rapid growth due to increasing healthcare expenditure and a large population base[1][3].

SWOT Analysis

A SWOT analysis provides a comprehensive view of the market:

  • Strengths: Established market presence, growing demand for OTC medications, and advancements in pharmaceutical technology.
  • Weaknesses: Regulatory challenges, misuse and addiction issues, and high competition.
  • Opportunities: Expanding into emerging markets, innovative formulations, and increasing healthcare needs.
  • Threats: Economic fluctuations, changes in consumer behavior, and stringent regulatory environments[1][3].

Market Outlook

The market outlook for doxylamine succinate is promising, with several factors shaping its future:

  • Growth Catalysts: Increasing demand, technological advancements, and expanding healthcare needs.
  • Constraints: Regulatory challenges, competition, and economic factors.
  • Opportunities and Challenges: Emerging markets, innovative formulations, and the need to address misuse and addiction issues[1][3].

Porter's 5 Forces Framework

This framework helps in understanding the competitive structure of the market:

  • Threat of New Entrants: Moderate due to regulatory barriers and the need for significant investment.
  • Bargaining Power of Suppliers: Low to moderate as suppliers are numerous and the market is competitive.
  • Bargaining Power of Buyers: Moderate to high as buyers have several options and are price-sensitive.
  • Threat of Substitute Products: Moderate as there are alternative antihistamines and sedatives available.
  • Competitive Rivalry Among Existing Competitors: High due to the presence of many established and emerging players[1][3].

Key Takeaways

  • The doxylamine succinate market is experiencing significant growth driven by increasing demand for OTC medications.
  • The market is segmented by type, application, and geography.
  • Key drivers include growing healthcare needs and advancements in pharmaceutical technology.
  • Regulatory challenges and misuse issues are significant restraints.
  • Emerging markets and innovative formulations present opportunities for growth.

FAQs

1. What are the primary applications of doxylamine succinate?

Doxylamine succinate is primarily used as an antihistamine, anticholinergic, and sedative. It is also used in other applications such as in the treatment of cold and flu symptoms[1][3].

2. Which regions are leading the doxylamine succinate market?

North America and Europe are currently the leading regions, but Asia-Pacific is expected to show significant growth in the future[1][3].

3. What are the major challenges facing the doxylamine succinate market?

The market faces challenges such as regulatory scrutiny, competition, economic fluctuations, and the issue of misuse and addiction[1][3].

4. How is the competitive landscape of the doxylamine succinate market?

The market is highly competitive with several established and emerging players. Companies like Teva, CHATTEM, and DUCHESNAY are prominent in the market[1][3].

5. What is the projected growth rate of the doxylamine succinate market?

The market is expected to grow at a notable CAGR from 2023 to 2031, driven by increasing demand and expanding applications[1][3].

Citations

  1. Market Research Intellect, "Doxylamine Succinate Market Size, Scope And Forecast Report," October 2024.
  2. White Light Behavioral Health, "Nyquil Addiction: Symptoms, Causes, Effects & Treatment," August 20, 2024.
  3. Cognitive Market Research, "Doxylamine Market Report 2024 (Global Edition)," October 19, 2022.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.